We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

19 hedge funds and large institutions have $2.43M invested in Cellectar Biosciences in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.09% less ownership

Funds ownership: 0.67% → 0.59% (-0.09%)

21% less funds holding

Funds holding: 24 → 19 (-5)

24% less capital invested

Capital invested by funds: $3.22M → $2.43M (-$785K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
19
Holders Change
-5
Holders Change %
-20.83%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$17.3K
2
UBS Group
UBS Group
Switzerland
+$731

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$284K
2
Citadel Advisors
Citadel Advisors
Florida
-$31.9K
3
Franklin Resources
Franklin Resources
California
-$17.7K
4
TRCT
Tower Research Capital (TRC)
New York
-$5.26K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.27K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$1.34M – – –
WVP
2
Worth Venture Partners
New Jersey
$485K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$251K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$82K +$17.3K +355 +23%
BlackRock
5
BlackRock
New York
$81.6K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$68K -$1.27K -26 -2%
MS
7
Maven Securities
Jersey
$35.8K – – –
State Street
8
State Street
Massachusetts
$22.6K – – –
Morgan Stanley
9
Morgan Stanley
New York
$21.4K – – –
1WM
10
1900 Wealth Management
Texas
$20.5K – – –
Bank of New York Mellon
11
Bank of New York Mellon
New York
$17.2K – – –
TRCT
12
Tower Research Capital (TRC)
New York
$7K -$5.26K -108 -42%
UBS Group
13
UBS Group
Switzerland
$3.02K +$731 +15 +27%
Osaic Holdings
14
Osaic Holdings
Arizona
$745 – – –
US Bancorp
15
US Bancorp
Minnesota
$408 – – –
Wells Fargo
16
Wells Fargo
California
$80 – – –
HI
17
Harbour Investments
Wisconsin
$57 – – –
AWM
18
AllSquare Wealth Management
New York
$26 – – –
MFG
19
Mendota Financial Group
Wisconsin
$4 – – –
CH
20
CVI Holdings
Delaware
– -$284K -5,535 Closed
Citadel Advisors
21
Citadel Advisors
Florida
– -$31.9K -622 Closed
Franklin Resources
22
Franklin Resources
California
– -$17.7K -345 Closed
MWM
23
MinichMacGregor Wealth Management
New York
– -$239 -5 Closed
Bank of America
24
Bank of America
North Carolina
– -$34 -1 Closed
TFA
25
Transamerica Financial Advisors
Florida
– -$1K – –

CLRB Hedge Fund Activity: Q1 2023 in Review

19 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2023, worth a combined $2.43M — down 24% from $3.22M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CLRB and 0 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $17.3K. The largest seller was CVI Holdings, exiting entirely with an estimated $284K sold.

  • 19 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2023, down from 24 in Q4 2022.
  • Funds reported $2.43M of Cellectar Biosciences stock for Q1 2023, down 24% quarter-over-quarter.
  • 0 funds opened new Cellectar Biosciences positions in Q1 2023 and 5 closed out, a net change of -5 holders.
  • The largest Cellectar Biosciences buyer in Q1 2023 was Renaissance Technologies, an estimated $17.3K added.
  • The largest Cellectar Biosciences seller in Q1 2023 was CVI Holdings, an estimated $284K sold.

Based on aggregated 13F filings for Q1 2023.